A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Disitamb Vedotin ,pyrotinib
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: First Affiliated Hospital of Wenzhou Medical University